Explore

Rapid ReadRapid Read
Evvy Secures $40 Million Series B to Advance Women's Health Research with Vaginal Microbiome Data

Evvy Secures $40 Million Series B to Advance Women's Health Research with Vaginal Microbiome Data

Evvy, a women's health company, announced it has raised $40 million in a Series B funding round led by Catalio Capital Management. Launched in 2021 by Priyanka Jain, Laine Bruzek, and Pita Navarro, Evvy is recognized for its at-home CLIA-certified and CLEP-certified mNGS test, which analyzes vaginal microbes using a single swab. Users send their samples to Evvy's lab for mNGS sequencing, with results reviewed by clinicians on its platform and then posted to the patient's health portal. The company states it has served over 100,000 patients across the United States and collaborates with 3,000 practitioners. Evvy has also contributed to 15 peer-reviewed publications and abstracts, identifying novel BV subtypes and hundreds of previously uncatalogued vaginal microbiome genomes. Clinicians utilizing Evvy's platform can leverage this data for personalized patient treatments. Beyond direct patient care, Evvy aims to build a comprehensive dataset linking microbiome biology, symptoms, interventions, and health out...
Rapid ReadRapid Read
University of Colorado Anschutz Researchers Link Exosomes to Lingering Shingles Pain

University of Colorado Anschutz Researchers Link Exosomes to Lingering Shingles Pain

Researchers at the University of Colorado Anschutz have identified extracellular vesicles, known as exosomes, as a likely cause of post-herpetic neuralgia (PHN), the persistent pain some individuals experience after a shingles infection. The study, led by Andrew Bubak, PhD, found that even after the varicella zoster virus (VZV) has cleared the body, exosomes released by nerve cells continue to transmit inflammatory signals. When healthy nerve cells were exposed to exosomes from PHN patients, they exhibited similar harmful changes seen during viral infection, despite the absence of the virus. This suggests that PHN may arise from a 'failure-to-resolve' model, where the body's healing response remains active, preventing nerves from recovering normally. The findings, published in *Annals of Neurology*, indicate that these exosomes sustain a state of inflammation and abnormal nerve remodeling, contributing to chronic pain.
Rapid ReadRapid Read
Memorial Sloan Kettering Cancer Center and OpenEvidence Partner to Integrate Precision Oncology Data into EHRs

Memorial Sloan Kettering Cancer Center and OpenEvidence Partner to Integrate Precision Oncology Data into EHRs

Memorial Sloan Kettering Cancer Center (MSK) and OpenEvidence have announced a partnership to advance precision oncology by integrating MSK's OncoKB™ knowledge base into OpenEvidence. This collaboration aims to provide clinicians nationwide with expert interpretation of cancer genomics directly within electronic health records (EHRs). OncoKB™, which is partially recognized by the U.S. Food and Drug Administration (FDA), offers evidence-based assertions on genetic alterations in cancer that can guide treatment decisions. The integration will allow OncoKB's curated content, including oncogenic effects, levels of evidence, and associated therapies, to be surfaced within OpenEvidence and Epic EHRs, alongside patient context. This initiative seeks to translate complex genomic reports into clear, evidence-based treatment paths, making MSK's expertise accessible to a broader network of cancer care providers across the U.S. More than half of U.S. hematologist-oncologists currently use OpenEvidence for complex onco...
TrendlineTrendline
Siensmetrica Appoints Former Wiley CEO Brian Napack to Advisory Board to Enhance AI-Powered Biomedical Research Evaluation

Siensmetrica Appoints Former Wiley CEO Brian Napack to Advisory Board to Enhance AI-Powered Biomedical Research Evaluation

Siensmetrica Appoints Former Wiley CEO Brian Napack to Advisory Board to Enhance AI-Powered Biomedical Research Evaluation
Rapid ReadRapid Read
Mizzou Alum John Ruth Drives $10 Million State Investment for Rare Disease Research, Establishes Center for Translational Neurogenetics

Mizzou Alum John Ruth Drives $10 Million State Investment for Rare Disease Research, Establishes Center for Translational Neurogenetics

John Ruth, a University of Missouri (Mizzou) alumnus, has spearheaded a significant initiative resulting in a $10 million investment from the state of Missouri to fund research into rare genetic disorders. This funding has led to the establishment of the Center for Translational Neurogenetics (CTN) at Mizzou. Ruth's advocacy was motivated by his daughter, Kamdyn, who was diagnosed with Baker-Gordon Syndrome, an ultra-rare neurodevelopmental disorder caused by an SYT1 gene mutation. Through the Genetic Autism Alliance, an independent nonprofit he founded, Ruth championed the cause for increased research into such conditions, which often lack private industry investment due to their rarity. Mizzou researchers at the CTN have already developed a gene-editing technique called CRISPR-SWITCH, creating a preclinical model of Baker-Gordon Syndrome that more accurately reflects the human condition, offering new avenues for study and potential therapeutic development.
TrendlineTrendline
North Texas Emerges as a Hub for Longevity Industry, Attracting Billions in Investment

North Texas Emerges as a Hub for Longevity Industry, Attracting Billions in Investment

North Texas Emerges as a Hub for Longevity Industry, Attracting Billions in Investment
Rapid ReadRapid Read
Omniscient Receives Third FDA Clearance for AI-Powered Deep Brain Stimulation Platform

Omniscient Receives Third FDA Clearance for AI-Powered Deep Brain Stimulation Platform

Omniscient, a company specializing in applying AI to brain connectomics, has secured its third 510(k) clearance from the U.S. Food and Drug Administration (FDA) for a new workflow within its Quicktome® platform. This new application, Quicktome Deep Brain (DB), extends the benefits of connectomic analysis to deep brain stimulation (DBS) procedures. The clearance marks Omniscient's entry into the neuromodulation market, specifically targeting the growing field of DBS. Quicktome DB aims to provide patient-specific insights for DBS lead placement by utilizing automated, FDA-cleared processing of individual patient imaging. This technology localizes leads, segments deep brain structures, and maps white matter tracts within the brain's networks, moving neurological care towards a more personalized approach. The platform is designed to be HIPAA-compliant and supports Abbott DBS systems, making personalized DBS programming accessible to a wider patient population.
Rapid ReadRapid Read
Inspire and AIRLIFT Offer Surgical Alternatives to CPAP for Obstructive Sleep Apnea

Inspire and AIRLIFT Offer Surgical Alternatives to CPAP for Obstructive Sleep Apnea

For individuals suffering from obstructive sleep apnea (OSA) who find CPAP therapy intolerable, alternative surgical options like Inspire hypoglossal nerve stimulation and AIRLIFT hyoid suspension are available. OSA occurs when the airway repeatedly narrows or collapses during sleep. Inspire addresses this by stimulating the hypoglossal nerve, which moves the tongue forward. In contrast, AIRLIFT hyoid suspension physically repositions and stabilizes a part of the airway. The choice between these treatments, or other alternatives, depends on the patient's specific anatomy, the severity of their OSA, previous treatments, the exact locations of airway collapse, and their treatment goals. It is crucial for treatment decisions to be based on an individual evaluation of the patient's anatomy and obstruction pattern, as sleep apnea is not caused by the same anatomical issues in every person. AIRLIFT can be a standalone procedure or part of a broader multilevel sleep surgery if multiple areas of the airway contrib...
TrendlineTrendline
Longevity Market Shifts Towards Holistic Solutions Integrating Functionality, Technology, and Ecosystems

Longevity Market Shifts Towards Holistic Solutions Integrating Functionality, Technology, and Ecosystems

Longevity Market Shifts Towards Holistic Solutions Integrating Functionality, Technology, and Ecosystems
Rapid ReadRapid Read
Tempus AI Launches Initiative to Build Largest Multimodal Whole-Genome Dataset for AI-Driven Healthcare

Tempus AI Launches Initiative to Build Largest Multimodal Whole-Genome Dataset for AI-Driven Healthcare

Tempus AI, Inc. (NASDAQ: TEM) has announced a new initiative to create a research platform containing 100,000 whole genomes linked to longitudinal clinical information over the next several years. This effort aims to establish the first de-identified multimodal whole-genome sequencing (WGS) dataset specifically optimized for AI-driven research, built around disease populations and patient outcomes. Following the completion of this initial dataset, Tempus plans to expand the project with a long-term goal of reaching one million genomes. Unlike existing population-scale genome programs that primarily draw from general populations, Tempus's dataset will integrate genomic data with longitudinal disease and treatment outcomes. The company has already developed one of the largest multimodal real-world oncology databases, which has been used to inform drug development decisions. This new WGS dataset will be incorporated into Tempus’ existing de-identified multimodal data environment, allowing researchers to acces...
TrendlineTrendline
Biohacking Clubs Gain Popularity Across the U.S., Offering Advanced Wellness Services

Biohacking Clubs Gain Popularity Across the U.S., Offering Advanced Wellness Services

Biohacking Clubs Gain Popularity Across the U.S., Offering Advanced Wellness Services
TrendlineTrendline
ZocDoc Launches 'Ready to Be Seen?' Campaign Emphasizing Personalized Doctor Selection

ZocDoc Launches 'Ready to Be Seen?' Campaign Emphasizing Personalized Doctor Selection

ZocDoc Launches 'Ready to Be Seen?' Campaign Emphasizing Personalized Doctor Selection